Eric Thompson, Ph.D.
@azbiomarkers.bsky.social
Precision medicine translational pharmacologist and cancer biologist, utilizing evidence based medicine to move biomarkers into the clinic. Views are my own.
The finance bros were way ahead of the curve - think Kronos that John Sperling had running in the mid 90's. They just need to hire Nicolas Flamel!
October 21, 2025 at 6:04 PM
The finance bros were way ahead of the curve - think Kronos that John Sperling had running in the mid 90's. They just need to hire Nicolas Flamel!
Any plans for the companies to drive strengthening of GINA so the risk of the data falling into underwriting hands is less acute? Genetic discrimination is legal outside of employment and health insurance.
October 20, 2025 at 2:38 AM
Any plans for the companies to drive strengthening of GINA so the risk of the data falling into underwriting hands is less acute? Genetic discrimination is legal outside of employment and health insurance.
Apologies - the decision support interpretation isn’t quite there outside of these Rx ( e.g. DPYD for fluoropyrimidines).
October 7, 2025 at 7:18 PM
Apologies - the decision support interpretation isn’t quite there outside of these Rx ( e.g. DPYD for fluoropyrimidines).
There are a couple of instances in cancer Rx when it is crucial, but the decision support interpretation isn’t quite there. I have these conversations all the time - en route to some now. Polite is all we can ask. We have to bring the science.
October 7, 2025 at 7:17 PM
There are a couple of instances in cancer Rx when it is crucial, but the decision support interpretation isn’t quite there. I have these conversations all the time - en route to some now. Polite is all we can ask. We have to bring the science.
Think I saw a recent announcement of a company re-entering this space. Have not checked their science.
October 7, 2025 at 7:10 PM
Think I saw a recent announcement of a company re-entering this space. Have not checked their science.
There is not enough data spanning the entire ADME enzymatic system to integrate findings into clinical decisions. There is not a monetary incentive to create these data. Until this is solved you are correct. The data existing often are not used (e.g. warfarin, irinoteca).
October 7, 2025 at 7:09 PM
There is not enough data spanning the entire ADME enzymatic system to integrate findings into clinical decisions. There is not a monetary incentive to create these data. Until this is solved you are correct. The data existing often are not used (e.g. warfarin, irinoteca).
Unless GINA is strengthened to include many more insurance utility cases this data will be sought by underwriters. It is their business model to accurately model risk, and these data can be a help for them. The harm to the subject is actually a win in this business setting. We need to expand GINA.
September 11, 2025 at 6:47 PM
Unless GINA is strengthened to include many more insurance utility cases this data will be sought by underwriters. It is their business model to accurately model risk, and these data can be a help for them. The harm to the subject is actually a win in this business setting. We need to expand GINA.
